Platelet aggregation and coagulation cascade

The platelet aggregation and coagulation cascade represents the integrated physiological system responsible for hemostasis and the prevention of blood loss following vascular injury. Platelet aggregation involves the activation and cross-linking of platelets via surface receptors like Glycoprotein IIb/IIIa and P2Y12, while the coagulation cascade is a proteolytic series of zymogen activations culminating in the conversion of fibrinogen to fibrin (StatPearls, Physiology, Coagulation Cascade, 2023). This system is a primary focus of cardiovascular medicine, as its pathological overactivation leads to arterial and venous thrombosis, resulting in myocardial infarction and stroke (NIH, National Heart, Lung, and Blood Institute, 2022). Therapeutic strategies target various nodes within this network, including cyclooxygenase-1 (Aspirin), P2Y12 receptors (Clopidogrel), and specific clotting factors like Factor Xa (Rivaroxaban) or Thrombin (Dabigatran) (PubChem, Compound Summary). While these interventions are critical for managing thrombotic risk, they inherently increase the risk of hemorrhage, necessitating careful monitoring of biomarkers such as the International Normalized Ratio (INR) or activated partial thromboplastin time (aPTT) (Merck Manual, Overview of Hemostasis, 2023).

Other names

HemostasisBlood clotting cascadeThrombogenesisCoagulation pathway

Pharmacological agents modulate this system by inhibiting platelet cyclooxygenase-1, antagonizing P2Y12 or Glycoprotein IIb/IIIa receptors, or directly/indirectly inhibiting coagulation factors such as Thrombin and Factor Xa to prevent fibrin formation (StatPearls, 2023).